Senhwa Biosciences Inc

Senhwa Biosciences Inc

TTPEX:6492
28.65
TWD
-0.25
(-0.87%)
-3.23EPS
3.93BMarket Cap
Senhwa Biosciences Inc
TPEX:6492
(Taipei Exchange)

Recent

price

28.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
0.57
0.35
- -
- -
- -
0.01
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Revenue per Share
- -
-2.44
-2.33
-2.81
-3.7
-4.92
-4.79
-5.1
-4.36
-3.56
-3.8
-3.22
-3.2
-2.88
-3.23
Basic EPS, GAAP
- -
-2.08
-2.15
-2.52
-3.22
-4.39
-4.78
-5.01
-3.35
-3.25
-4.35
-3.25
-3.22
-2.71
-2.7
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.09
12.39
13.1
10.59
7.38
20.01
15.42
10.56
25.18
21.39
17.56
14.33
11.17
8.26
12.09
Book Value per Share
6.09
12.39
13.09
10.59
7.37
20.01
15.41
10.56
25.18
21.39
17.56
14.33
11.17
8.26
12.09
Tangible Book Value per Share
66
46
67
69
69
76
78
77
81
92
92
92
92
92
98
Basic Weighted Avg Shares
- -
26
24
- -
- -
- -
1
- -
1
1
1
1
1
1
1
Sales/Revenue/Turnover
- -
-442.77
-690.71
- -
-201,574.22
- -
-52,860.57
-131,266.67
-58,226.74
-62,966.55
-35,611.5
-31,111.1
-30,619.1
-26,005.51
-33,737.71
Operating Margin (%)
- -
- -
- -
1
1
2
3
8
7
6
7
11
12
12
11
Depreciation Expense
- -
-113
-156
-194
-255
-372
-376
-391
-355
-329
-350
-296
-294
-265
-315
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-430.96
-658.74
- -
-199,230.47
- -
-51,275.58
-130,475.33
-57,516.69
-59,864.91
-34,963.2
-29,630.6
-29,374.5
-24,744.77
-32,855.1
Profit Margin (%)
330
742
831
724
505
1,559
1,204
820
2,322
1,963
1,605
1,293
1,004
735
1,355
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
8
10
8
3
8
13
6
LT Debt
399
812
904
731
512
1,568
1,209
829
2,326
1,969
1,614
1,317
1,027
761
1,383
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-18.69
-18.14
-23.73
-41.05
-35.76
-27.06
-38.41
-22.5
-15.33
-19.52
-20.22
-25.06
-29.62
-28.4
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
10
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
11
8
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
114
Market Capitalization
4,505
3,808
3,929

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
695
645
1,418
Cash, Cash Equivalents & STI
688
637
1,378
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
54
63
Payables & Accruals
- -
- -
- -
ST Debt
10
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.31%
-19.94%
-25.91%
Free Cash Flow
6.46%
0.2%
-16.02%
Net Income, GAAP
4.61%
-5.4%
-9.86%
Sales/Revenue/Turnover
- -
- -
7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.69
-0.76
-0.88
-0.87
-3.2
2025
-0.67
-0.61
-0.72
-0.88
-2.88
2026
-0.73
-0.89
-0.74
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Senhwa Biosciences, Inc. (6492.TWO) is a clinical-stage biotechnology company focused on developing next-generation DNA Damage Response (DDR) therapeutics and targeted agents for cancer treatment, rare diseases, and related indications. The company advances a pipeline of first-in-class small molecule drugs, including its lead candidate Pidnarulex (CX-5461), a G-quadruplex stabilizer targeting solid tumors such as ovarian cancer, breast cancer, MYC-aberrant B-cell lymphoma, refractory microsatellite stable colorectal cancer, and hematologic malignancies; and Silmitasertib (CX-4945), a Casein Kinase 2 inhibitor for cholangiocarcinoma, basal cell carcinoma, medulloblastoma, and neuroblastoma. Clinical trials for these programs span Phase 1 through Phase 2 across monotherapy, combination with immunotherapy (including PD-1 inhibitors), and antibody-drug conjugates, conducted in collaboration with partners in the United States, Canada, Australia, South Korea, and Taiwan; additional exploratory applications include HIV functional cure and immune microenvironment modulation to convert cold tumors to hot tumors. Founded in 2012 and headquartered at 10F, No. 225, Sec. 3, Peihsin Rd., Hsintien Dist., New Taipei City, Taiwan, with a key operational subsidiary in San Diego, California, USA, Senhwa Biosciences conducts global R&D and leverages service providers across North America, Asia, Australia, and Europe to advance its programs toward proof-of-concept and commercialization. The company listed on the Taipei Exchange in 2017 and targets unmet needs in oncology, including HRD-deficient cancers, MYC-driven lymphomas, and pediatric rare tumors, with orphan drug and rare pediatric disease designations for multiple CX-4945 indications providing regulatory incentives such as tax credits and market exclusivity. Recent developments include a five-year collaboration agreement with the U.S. National Cancer Institute (NCI) under the NIH's NExT program in 2024 to support CX-5461 advancement in MYC-driven lymphoma and cross-cancer indications, with IND submissions and patient enrollment underway; partnerships with the Pediatric Brain Tumor Consortium (PBTC) and others for medulloblastoma trials; and strategic alliances with global PD-1 leaders announced in October 2025 to combine CX-5461 with immunotherapy for broader oncology applications. In June 2025, Senhwa highlighted breakthroughs at its annual shareholders' meeting, including long-term survival data in pancreatic cancer patients and plans for trial completion and out-licensing in 2026; the company also explores HIV applications for CX-4945 based on its immune-modulating effects. These initiatives reflect Senhwa's shift toward combination therapies, NCI-sponsored expansions, and global licensing to enhance pipeline value.